BUZZ-Australia's Nexsen rises on early rollout of GBS screening test** Nexsen NXN.AX rises as much as 9.1% to A$0.180
** Stock on track for third consecutive session of gains
** Nano biotech firm executes global rollout strategy for StrepSure
** Co to enable early market entry across U.S., India, Hong Kong, other select regions while progressing towards U.S. regulatory approval
** Co targets U.S. FDA submission in Q4 2026
** StrepSure is a test to detect Group B Streptococcus (GBS) bacteria - which causes pneumonia, meningitis and others - in pregnant women
** YTD, NXN gains 12.5%
(Reporting by Aamir Sheik Khalid in Bengaluru)
((Aamir.SheikKhalid@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.